ClinicalTrials.gg
Not yet recruitingNCT07622641Timing-MidazolUpdated Jun 10, 2026

Timing Of Midazolam İn Children Undergoing Adenotonsillectomy: Effects On Stress, Cortisol, And Recovery

An interventional study of Midazolam (Oral) and Midazolam (Intravenous) in Adenotonsillectomy, Preoperative Anxiety and Surgical Stress Response, sponsored by Erzurum City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Erzurum City Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing midazolam in Pain, Postoperative — 3 open to participants now, 3 under way, none of them phase 3. Midazolam · Pain, Postoperative.

Planned enrollment
5th of 13
100 · median 90
Started
2026
the only one that year
No phase
4 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Erzurum City Hospital

Among the 13 studies testing midazolam in Pain, Postoperative, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 4 with no phase, and was the 13th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 13 studies testing midazolam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About midazolam

Midazolam: first FDA approval 1985 (VERSED), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing midazolam in Pain, Postoperative, or all of them as a file.
02

Study summary

This study is a prospective, randomized, controlled clinical trial designed to evaluate the optimal timing of midazolam administration in children undergoing adenotonsillectomy. The study will be conducted at the Departments of Otorhinolaryngology and Anesthesiology of Erzurum City Hospital.

Midazolam is commonly used in pediatric patients to reduce anxiety and improve perioperative comfort. However, the optimal timing of its administration (before surgery or during anesthesia induction) remains unclear. This study aims to compare the effects of preoperative oral midazolam and intraoperative intravenous midazolam on stress response, behavioral outcomes, and recovery quality.

Participants will be randomly assigned to one of two groups. In Group A, children will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery. In Group B, children will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.

The primary outcome of the study is the change in serum cortisol levels, which reflects the physiological stress response. Blood samples will be collected twice: once 10 minutes after anesthesia induction and once 15 minutes after surgery in the post-anesthesia care unit.

In addition to cortisol levels, the study will assess preoperative anxiety using an observational anxiety scale, postoperative pain using a behavioral pain scoring system, and parental satisfaction using a standardized questionnaire. These measures aim to provide a comprehensive evaluation of the child's perioperative experience.

The findings of this study may help determine the most effective timing of midazolam administration to reduce stress, improve recovery, and enhance overall patient and family satisfaction in pediatric surgical care.

Read the detailed description

This study is a prospective, randomized, controlled clinical trial designed to evaluate the effects of the timing of midazolam administration on physiological stress response, behavioral anxiety, postoperative pain, recovery quality, and parental satisfaction in pediatric patients undergoing elective adenotonsillectomy.

The primary objective is to compare the effect of midazolam administration timing on physiological stress response, assessed by serum cortisol levels. Secondary objectives include evaluating preoperative anxiety levels, postoperative pain scores, recovery quality, and parental satisfaction between groups receiving midazolam at different time points.

The study will include children aged 3-10 years, classified as ASA physical status I-II, scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy.

Eligible patients will be identified during preoperative anesthesia evaluation. Parents or legal guardians will be informed about the study, and written informed consent will be obtained prior to enrollment.

Participants will be randomly assigned to one of two groups using a computer-generated randomization sequence with sealed envelope allocation:

Group A (Preoperative Midazolam Group): Patients will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery, administered with a small volume of apple juice under clinical supervision.

Group B (Intraoperative Midazolam Group): Patients will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.

Anesthesia Protocol

To ensure comparability between groups, all patients will undergo a standardized anesthesia protocol. Vascular access will be established after inhalational induction using sevoflurane in oxygen, minimizing stress associated with intravenous cannulation.

Lidocaine (0.5-1 mg/kg) will be administered prior to propofol injection to reduce injection pain Propofol (2-3 mg/kg) will be used for induction Rocuronium (0.6 mg/kg) will be administered for neuromuscular blockade Fentanyl (1-2 µg/kg) will be used for analgesia

Anesthesia maintenance will be achieved with sevoflurane (2-3%) in a mixture of oxygen and air, targeting an age-adjusted MAC ≥1.3. Mechanical ventilation will be standardized with volume-controlled settings appropriate for age.

Intraoperative fluid management will be based on body weight using standard pediatric maintenance formulas and isotonic saline solution.

Neuromuscular blockade will be reversed with sugammadex (2 mg/kg) Extubation will be performed based on clinical recovery criteria, including adequate spontaneous respiration and responsiveness

All patients will receive intravenous paracetamol (10-15 mg/kg) for postoperative analgesia and ondansetron (0.1 mg/kg) for prophylaxis of nausea and vomiting.

Serum cortisol levels will be measured at two time points:

Intraoperative period (10 minutes after anesthesia induction) Early postoperative period (15 minutes after admission to the post-anesthesia care unit)

Cortisol levels will be analyzed using an electrochemiluminescence immunoassay method.

Preoperative anxiety will be assessed using a modified observational anxiety scale. Postoperative pain will be evaluated using a validated behavioral pain scoring system, and recovery status will be assessed using standard recovery criteria.

Parental satisfaction will be evaluated within the first 30 minutes after surgery using a structured questionnaire assessing overall perioperative experience.

All perioperative data will be recorded by the anesthesia team and post-anesthesia care unit staff. Collected data will be analyzed statistically to compare outcomes between the two groups.

03

Conditions studied

  • Adenotonsillectomy
  • Preoperative Anxiety
  • Surgical Stress Response
  • Postoperative Pain

Browse trials for

Keywords

  • Midazolam
  • Pediatric Anesthesia
  • Adenotonsillectomy
  • Premedication Timing
  • Preoperative Anxiety
  • Cortisol Response
  • Postoperative Pain
  • Recovery Quality
04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3-10 years,
  • Scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy,
  • (ASA) physical status I-II,
  • Written obtained from parents or legal guardians

Exclusion criteria

Exclusion Criteria:

  • Children younger than 3 years or older than 10 years,
  • (ASA) physical status greater than II,
  • Known allergy to apple or apple-derived products,
  • Known allergy or to benzodiazepines,
  • Presence of developmental delay,
  • History of neuropsychiatric disorders,
  • Current or recent use of ,
  • Expected or actual surgical duration longer than 90 minutes,
  • Refusal of participation by parents or legal guardians
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Preoperative Oral Midazolam

    Participants in this group will receive oral midazolam at a dose of 0.5 mg/kg, administered 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration and improve tolerance.

    Drug: Midazolam (Oral)

  • Experimental
    Intraoperative Intravenous Midazolam

    Participants in this group will receive intravenous midazolam at a dose of 0.05-0.1 mg/kg during anesthesia induction.

    Drug: Midazolam (Intravenous)

Interventions

  • DrugMidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral midazolam will be administered at a dose of 0.5 mg/kg, 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration.

  • DrugMidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous midazolam will be administered at a dose of 0.05-0.1 mg/kg during anesthesia induction.

06

What researchers measure

Primary outcomes

  1. Change in Serum Cortisol Levels

    Serum cortisol levels will be measured to assess physiological stress response.

    Time frame: At 10 minutes after anesthesia induction and at 15 minutes postoperatively in the post-anesthesia care unit (PACU)

Secondary outcomes

  1. Preoperative Anxiety Level (mYPAS Score)

    Preoperative anxiety will be assessed using the modified Yale Preoperative Anxiety Scale (mYPAS), an observational tool evaluating behavioral anxiety in children across multiple domains. Scores will be normalized to a 0-100 scale, with higher scores indicating greater anxiety.

    Time frame: During the preoperative period before anesthesia induction

  2. Postoperative Pain Score (FLACC Score)

    Postoperative pain will be evaluated using the FLACC (Face, Legs, Activity, Cry, Consolability) scale, a validated behavioral pain assessment tool for pediatric patients. Each category is scored from 0 to 2, with a total score ranging from 0 to 10, where higher scores indicate more severe pain.

    Time frame: At 15 minutes postoperatively in the post-anesthesia care unit (PACU)

  3. Recovery Status (Modified Aldrete Score)

    Recovery status will be assessed using the Modified Aldrete Score, which evaluates activity, respiration, circulation, consciousness, and oxygen saturation. Higher scores indicate better recovery and readiness for discharge from the PACU.

    Time frame: Within the first 30 minutes postoperatively in the PACU

  4. Parental Satisfaction (PAPS Survey)

    Parental satisfaction will be evaluated using the Pediatric Anesthesia Parent Satisfaction (PAPS) survey, a structured questionnaire assessing satisfaction with perioperative care, including communication, pain management, and overall experience. Scores range from 5 to 25, with higher scores indicating greater satisfaction.

    Time frame: Within 30 minutes after the child becomes clinically stable in the postoperative period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be publicly available due to institutional and ethical restrictions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622641
Lead sponsor
Erzurum City Hospital
Responsible party
Mehmet Sercan Orbak (Anesthesiology Specialist (MD), Principal Investigator, Erzurum City Hospital) — Principal investigator
First posted
Jun 3, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Mehmet Sercan Orbak, MD
Contact
sercanorbak@gmail.com
+ 90 (506) 288 35 34
Ahmet Ergün, MD
Contact
draergn@gmail.com
Mehmet Sercan Orbak, MD
principal investigator · Erzurum City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion